- |||||||||| carbidopa/levodopa / Generic mfg.
PK/PD data, Journal: Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. (Pubmed Central) - Jan 23, 2021
An additional nutritional supplementation with methyl group donating and free radical scavenging vitamins is recommendable, when future drugs are developed for long term levodopa/dopa decarboxylase treated patients. Personalised medicine treatment concepts shall also consider nutritional aspects in Parkinson's disease.
- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, Journal: New Therapeutic Options for the Individualised Titration of Levodopa (Pubmed Central) - Jan 23, 2021
For this reason, the introduction of water-soluble microtablets à 5 / 1.25 mg levodopa / carbidopa can be regarded as a beneficial extension permitting for fine titration of the dopaminergic stimulation. Here we present this new therapeutic principle, the available data and concepts for clinical use.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Parkinson Disease. (Pubmed Central) - Jan 1, 2021
Motor symptoms are managed with carbidopa/levodopa, monoamine oxidase-B inhibitors, and nonergot dopamine agonists...Nonmotor symptom therapies target patient-specific conditions during the disease course. Interdisciplinary team care can alleviate multiple symptoms of Parkinson disease.
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Dec 11, 2020
P2, N=32, Completed,
Therefore, in PD patients where impaired motor performance develops and the application of entacapone is necessary, it is suggested to be administered in a single tablet form. Recruiting --> Completed | N=52 --> 32 | Trial completion date: Mar 2021 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) - Dec 11, 2020
P2, N=35, Completed,
Recruiting --> Completed | N=52 --> 32 | Trial completion date: Mar 2021 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020 Recruiting --> Completed | N=52 --> 35 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Mar 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Dec 11, 2020
P2, N=21, Completed,
Recruiting --> Completed | N=52 --> 35 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Mar 2020 Recruiting --> Completed | N=52 --> 21 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Dec 2019
- |||||||||| levodopa/carbidopa SC (ABBV-951) / AbbVie
Journal, HEOR: Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden. (Pubmed Central) - Dec 10, 2020
Consecutive advanced PD patients treated with levodopa/carbidopa intestinal gel (LCIG) or continuous subcutaneous apomorphine infusion (CSAI) or care as usual (CU) and their care partners were recruited during routine visits according to a cross-sectional design...Patients treated with LCIG were more independent in taking a bath or shower without assistance and were more able to move and walk without assistance. Care partners of advanced PD patients treated with device-aided therapies have more time for their own life and a better perception of their QoL with a tendency to an improvement of mood compared with those of patients treated with CU.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Novel BSN Gene Mutation with Intractable Epileptic Encephalopathy () - Nov 28, 2020 - Abstract #AES2020AES_1028;
(1998) found that BSN is widely distributed in synapses throughout the adult rat brain. Its location is concentrated at presynaptic terminals of hippocampal neurons, suggesting it serves specific functions at synaptic junctions.
- |||||||||| carbidopa/levodopa / Generic mfg.
Observational data, Retrospective data, Journal: Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study. (Pubmed Central) - Nov 26, 2020
We aimed to study the effects of Levodopa-Carbidopa therapy in 2 separate groups: one with intrajejunal administration of Levodopa-Carbidopa gel and the second with oral therapy.We performed an observational retrospective Romanian cohort study on 61 patients diagnosed with PD patients, with Hoehn and Jahr 3 and 4 stages, recruited from a single regional tertiary center in Cluj-Napoca, Romania, between 2009 and 2019.The mean adjusted UPDRS III (and similarly for UPDRS II) improved in the LCIG compared to the oral therapy group with 15.6 (95% CI 12.0-19.2, P < .001), and with 18.4 (95% CI 13.8-22.9, P < .001), stratified for the Hoehn and Jahr stages 3 and 4. There was a 41.7% (10) reduction in dyskinesia, and 29.2% reduction in wearing off/on-off at 1 year in the LCIG group compared to 0% (0) dyskinesia reduction, and 2.7% reduction in wearing off/on-off in the oral therapy group.Continuous intrajejunal infusion of LCIG ensures a significant and clinical reduction in motor fluctuations compared to oral therapy in advanced PD, even after adjustment for important confounders.
- |||||||||| chlorpromazine / Generic mfg.
Preclinical, Journal: An evaluation of the effects of pyridoxal phosphate in chlorpromazine-induced Parkinsonism using mice. (Pubmed Central) - Nov 25, 2020
There was a 41.7% (10) reduction in dyskinesia, and 29.2% reduction in wearing off/on-off at 1 year in the LCIG group compared to 0% (0) dyskinesia reduction, and 2.7% reduction in wearing off/on-off in the oral therapy group.Continuous intrajejunal infusion of LCIG ensures a significant and clinical reduction in motor fluctuations compared to oral therapy in advanced PD, even after adjustment for important confounders. Pyridoxal phosphate supplementation was associated with significant benefits in CPZ-induced Parkinsonism-like changes in mice.
- |||||||||| Review, Journal: Chronic Pain Treatment Strategies in Parkinson's Disease. (Pubmed Central) - Nov 23, 2020
Anticonvulsants such as gabapentin, pregabalin, lamotrigine, carbamazepine and tricyclic antidepressants (TCAs) can be trialed when attempting to manage chronic pain in PD...A treatment plan can be devised that may include dopaminergic agents, acetaminophen, NSAIDs, opioids, antidepressants, physical therapies, DBS and other options discussed in this review. A thorough assessment of patient history and physical examination should be made in patients with PD so chronic pain may be managed effectively.
- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, Journal: Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent. (Pubmed Central) - Nov 12, 2020
We also did a comparative review of all published cases of dengue-induced parkinsonism. Post-dengue, parkinsonism is uncommon, and treating clinicians should be aware of this uncommon but treatable neurological complication of a common arboviral infection.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease. (Pubmed Central) - Nov 1, 2020
Here, we describe a few approaches that could be used alone or perhaps in combination to achieve a greater mosaic of behavioral benefit. These include (1) using encapsulated, genetically modified cells as delivery vehicles for administering neuroprotective trophic factors, such as GDNF, in a direct and sustained means to the brain; (2) immunotherapeutic interventions, such as vaccination or the use of monoclonal antibodies against aggregated, pathological α-synuclein; (3) the continuous infusion of levodopa-carbidopa through an intestinal gel pad to attenuate the loss of dopaminergic function and manage the motor and non-motor complications in PD patients; and (4) specific rehabilitation treatment programs for drug-refractory motor complications.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Von Hippel Lindau Disease And An Almost Pheochromocytoma () - Oct 17, 2020 - Abstract #ASA2020ASA_1594;
A 62-year-old female with Von Hippel-Lindau (VHL) disease, hypertension and Parkinson's disease under treatment with carbidopa/levodopa was proposed for laparoscopic left partial nephrectomy...The adrenal incidentaloma was therefore a nonfunctioning adenoma, not requiring preoperative blockade. Surgical procedure was uneventful.
- |||||||||| risperidone / Generic mfg., Egis
[VIRTUAL] Coincidental POLG Mutation Found in a Case of Drug-Induced Parkinsonism () - Sep 30, 2020 - Abstract #ANA2020ANA_634;
POLG1 mutation spectrum- Parkinsonism, PEO/ptosis, myopathy, polyneuropathy, ataxia, encephalopathy, epilepsy, cognitive impairment, psychiatric disorders, sensorineural hearing loss, dysarthria/dysphagia, hepatopathy, hypogonadism, cataracts, premature ovarian failure, and so forth. 2.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Acquired Movement Disorders Secondary to Tumefactive Virchow Robin Spaces () - Sep 30, 2020 - Abstract #ANA2020ANA_611;
Unilateral dystonia, ataxia, tremor, as well as skew deviation and torticollis, have remained largely unchanged over the years, and trials of carbidopa/levodopa have been unsuccessful in reducing symptoms. This case highlights that dilated perivascular spaces are not always benign entities and can result in complex neurologic presentations, even in pediatric patients.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Rapid-Onset Dystonia Parkinsonism: Evolution of Clinical Phenotype 26 Years Post Diagnosis () - Sep 30, 2020 - Abstract #ANA2020ANA_263;
suggested a consistent and unique phenotype consisting of rapid onset dystonia and parkinsonism initially, with slow or no progression. We now know that a spectrum of clinical presentations are possible with the ATP1A3 mutations that include classic RDP, classic RDP with intermittent worsening, slowly progressive Dystonia Parkinsonism, alternating hemiplegia of childhood, alternating hemiplegia with evolution to dystonia parkinsonism, and combinations involving seizures and Cerebellar ataxia, Areflexia, Pes Cavus, Optic atrophy and Sensorineural hearing loss (CAPOS) syndrome.
- |||||||||| Trial initiation date: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) (clinicaltrials.gov) - Sep 29, 2020
P4, N=90, Not yet recruiting,
We now know that a spectrum of clinical presentations are possible with the ATP1A3 mutations that include classic RDP, classic RDP with intermittent worsening, slowly progressive Dystonia Parkinsonism, alternating hemiplegia of childhood, alternating hemiplegia with evolution to dystonia parkinsonism, and combinations involving seizures and Cerebellar ataxia, Areflexia, Pes Cavus, Optic atrophy and Sensorineural hearing loss (CAPOS) syndrome. Initiation date: Sep 2020 --> Dec 2020
- |||||||||| Comtan (entacapone) / Novartis, Orion, pramipexole IR / Generic mfg., amantadine / Generic mfg.
[VIRTUAL] POLR3A Leukodystrophy presenting with levodopa responsive parkinsonism () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_1292;
Her symptoms were clearly levodopa responsive, however she began suffering from severe motor fluctuations requiring increased levopdopa intake and addition of entacapone...Her current medications include sinemet 5 times daily, amantadine twice daily and pramipexole 3 times daily... Given the severity of her motor fluctuations and dyskinesia these features are now her major source of disability and she is due to undergo deep brain stimulation surgery, the results of which will be presented.
- |||||||||| clonazepam / Generic mfg., carbidopa/levodopa / Generic mfg.
[VIRTUAL] Intracranial Tuberculous Abcess with Acute Parkinsonism: Unusual Finding () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_1180;
This case highlights the importance of recognizing CNS tuberculous infection as part of the aetiology of acute parkinsonism which might be developed due to reversible damage to basal ganglia. To avoid treatment delay, sending pus and biopsy sample for MTB culture and TB PCR are highly recommended especially in endemic country
- |||||||||| carbidopa/levodopa / Generic mfg., Madopar (levodopa/benserazide) / Roche
[VIRTUAL] Risk Factors and Subtypes of Ischemic Stroke in Patients with Parkinson’s Disease () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_1164;
PD patients had broad range of IS risk factors, which can lead to various subtype of IS. In our study most prevalent IS risk factors in PD patient was atrial fibrillation, which cause consequently cardioembolic stroke. Cardioembolic stroke PD patients had more severe neurological deficits than non-cardioembolic stroke PD patient. Further studies are required to understand epidemiology and risk factors of ischemic stroke patients with Parkinson’s disease, which may have big impact on prevention, management, and prognosis of the stroke in these patients population.
- |||||||||| Inbrija (levodopa inhalation powder) / Acorda
[VIRTUAL] Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_1108;
Oral carbidopa/levodopa (CD/LD) has limited utility as a treatment medication in patients with severe akinesia involving oropharyngeal muscles and impaired swallowing, and in patients with gastroparesis, can lead to delayed LD absorption...Case 2: 70-year-old patient on LD/CD intestinal gel (LCIG) presented to ED with altered mental status, respiratory distress, autonomic instability, and severe rigidity, BP 185/110, HR 120, RR 25, O2 sats 90%... CVT-301 (inhaled LD) administration in patients with acute complicated OFF episodes rapidly improved their OFF symptoms and prevented an ED visit, unnecessary and costly acute workup, or hospital admission.
- |||||||||| Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus
[VIRTUAL] Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_1092;
CVT-301 (inhaled LD) administration in patients with acute complicated OFF episodes rapidly improved their OFF symptoms and prevented an ED visit, unnecessary and costly acute workup, or hospital admission. In our real clinical practice experience with advanced PD patients, higher doses of safinamide significantly improved motor fluctuations as measured by UPDRS IV, being overall well tolerated.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_929;
In this study we did not find that earlier start of levodopa induced more motor response fluctuations and dyskinesias at 80 weeks. Patients with early PD without disability can gain quality of life by a use of a low dose of levodopa.
- |||||||||| Comtan (entacapone) / Novartis, Orion, carbidopa/levodopa / Generic mfg.
[VIRTUAL] Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy () - Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_911;
P1, P3
Background: ND0612 is in development as the first drug-device combination delivering liquid LD/CD via continuous SC infusion to reduce motor complications in patients with Parkinson’s disease (PD)...Body weight was included as a structural predictor of the disposition parameters for both compounds based on allometry principles; entacapone coadministration was also a structural covariate on LD bioavailability which was increased under a combination treatment setting. Model diagnostics for the LD and CD population PK models indicated a satisfactory predictive performance, supporting their usability to derive individual predictions of exposure to be used in future PK-pharmacodynamic analyses.
|
